US Stock MarketDetailed Quotes
AVNS Avanos Medical
- 18.120
- -0.560-3.00%
Close Nov 18 16:00 ET
- 18.120
- 0.0000.00%
Pre 08:02 ET
832.74MMarket Cap53.29P/E (TTM)
18.820High17.980Low318.11KVolume18.660Open18.680Pre Close5.81MTurnover0.76%Turnover RatioLossP/E (Static)45.96MShares25.36052wk High0.68P/B762.77MFloat Cap17.39052wk Low--Dividend TTM42.10MShs Float72.960Historical High--Div YieldTTM4.50%Amplitude17.235Historical Low18.266Avg Price1Lot Size
Avanos Medical Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -20.96%23M | 1,169.23%27.8M | -17.65%-8M | -64.36%32.4M | -62.31%12.7M | 2.46%29.1M | -109.63%-2.6M | -477.78%-6.8M | 4.12%90.9M | -35.32%33.7M |
| Net income from continuing operations | 216.22%4.3M | 102.64%1.8M | -80.00%-900K | -222.38%-61.8M | -37.87%10.5M | -123.57%-3.7M | -644.80%-68.1M | -109.26%-500K | 701.59%50.5M | 46.96%16.9M |
| Operating gains losses | --100K | --0 | --300K | 6,509.09%72.7M | --71.6M | ---- | ---- | ---- | -86.25%1.1M | ---- |
| Depreciation and amortization | 6.36%11.7M | -1.74%11.3M | -5.79%11.4M | -3.35%46.1M | -14.18%11.5M | -5.17%11M | -0.86%11.5M | 9.01%12.1M | 24.54%47.7M | 41.05%13.4M |
| Change In working capital | -82.04%3.7M | 161.94%8.3M | -13.99%-22M | 25.93%-18M | -268.75%-5.9M | 705.88%20.6M | -1,016.67%-13.4M | -6.63%-19.3M | -199.18%-24.3M | -112.60%-1.6M |
| -Change in receivables | -169.37%-7.7M | -1.37%-7.4M | -68.70%8.2M | 257.89%39M | 148.13%9M | 1,133.33%11.1M | -182.95%-7.3M | 266.88%26.2M | -128.70%-24.7M | 61.04%-18.7M |
| -Change in inventory | -70.77%1.9M | 31.11%-3.1M | 45.35%-4.7M | 115.21%4.7M | 130.61%11.3M | 136.52%6.5M | 68.09%-4.5M | -120.51%-8.6M | -296.82%-30.9M | -15.52%4.9M |
| -Change in prepaid assets | 1,950.00%3.7M | 121.05%4.2M | 86.67%-200K | -753.33%-19.6M | -3,860.00%-19.8M | -106.90%-200K | 280.00%1.9M | -1,600.00%-1.5M | 257.89%3M | 83.33%-500K |
| -Change in payables and accrued expense | 81.25%5.8M | 517.14%14.6M | 28.53%-25.3M | -248.76%-42.1M | -150.39%-6.4M | -69.81%3.2M | -197.22%-3.5M | -2,628.57%-35.4M | 31.63%28.3M | -78.07%12.7M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -20.96%23M | 1,169.23%27.8M | -17.65%-8M | -64.36%32.4M | -62.31%12.7M | 2.46%29.1M | -109.63%-2.6M | -477.78%-6.8M | 4.12%90.9M | -35.32%33.7M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 75.46%-12M | 9.23%-5.9M | 50.00%-2M | 115.95%21.6M | 1,753.06%81M | -940.43%-48.9M | -58.54%-6.5M | 96.71%-4M | -544.76%-135.4M | -4.26%-4.9M |
| Capital expenditure reported | 23.08%-3M | -47.50%-5.9M | -2.50%-4.1M | 7.77%-17.8M | -20.41%-5.9M | 26.42%-3.9M | 2.44%-4M | 20.00%-4M | 8.10%-19.3M | -4.26%-4.9M |
| Net business purchase and sale | --0 | --0 | --2.1M | 133.94%39.4M | --39.4M | --0 | --0 | --0 | ---116.1M | ---- |
| Net other investing changes | ---- | ---- | ---- | ---- | ---- | -7,600.00%-45M | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 75.46%-12M | 9.23%-5.9M | 50.00%-2M | 115.95%21.6M | 1,753.06%81M | -940.43%-48.9M | -58.54%-6.5M | 96.71%-4M | -544.76%-135.4M | -4.26%-4.9M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -134.26%-16M | -21.95%-5M | 96.83%-700K | -266.14%-94.2M | -423.74%-114.7M | 557.84%46.7M | 75.74%-4.1M | -120.91%-22.1M | 202.53%56.7M | 15.12%-21.9M |
| Net issuance payments of debt | -124.00%-13.2M | 0.00%-1.5M | 138.89%8.4M | -162.57%-64.7M | -347.22%-96.6M | --55M | ---1.5M | -117.28%-21.6M | 306.80%103.4M | -44.00%-21.6M |
| Net common stock issuance | 98.91%-100K | -34.62%-3.5M | -727.27%-9.1M | 58.02%-19.1M | -1,450.00%-6.2M | 16.36%-9.2M | 82.31%-2.6M | 94.33%-1.1M | -295.65%-45.5M | 96.33%-400K |
| Proceeds from stock option exercised by employees | -33.33%600K | --0 | -16.67%500K | -23.53%1.3M | -300.00%-200K | 12.50%900K | --0 | -14.29%600K | -72.58%1.7M | 0.00%100K |
| Net other financing activities | ---3.3M | --0 | ---500K | -303.45%-11.7M | ---- | ---- | ---- | ---- | ---2.9M | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -134.26%-16M | -21.95%-5M | 96.83%-700K | -266.14%-94.2M | -423.74%-114.7M | 557.84%46.7M | 75.74%-4.1M | -120.91%-22.1M | 202.53%56.7M | 15.12%-21.9M |
| Net cash flow | ||||||||||
| Beginning cash position | 12.71%92.2M | -20.79%75.8M | -31.32%87.7M | 7.76%127.7M | -8.46%107.1M | -23.19%81.8M | -8.25%95.7M | 7.76%127.7M | 6.28%118.5M | 19.63%117M |
| Current changes in cash | -118.59%-5M | 228.03%16.9M | 67.48%-10.7M | -429.51%-40.2M | -404.35%-21M | 99.26%26.9M | -320.00%-13.2M | -131.69%-32.9M | 10.91%12.2M | -68.06%6.9M |
| Effect of exchange rate changes | 212.50%1.8M | 28.57%-500K | -233.33%-1.2M | 106.67%200K | -57.89%1.6M | 46.67%-1.6M | 81.58%-700K | --900K | 25.00%-3M | 522.22%3.8M |
| End cash Position | -16.90%89M | 12.71%92.2M | -20.79%75.8M | -31.32%87.7M | -31.32%87.7M | -8.46%107.1M | -23.19%81.8M | -8.25%95.7M | 7.76%127.7M | 7.76%127.7M |
| Free cash flow | -20.63%20M | 431.82%21.9M | -12.04%-12.1M | -79.61%14.6M | -76.39%6.8M | 9.09%25.2M | -128.82%-6.6M | -237.50%-10.8M | 7.99%71.6M | -39.24%28.8M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data